Therapeutic targeting of TGF-beta in cancer: hacking a master switch of immune suppression

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

  2021cited by this paper
• TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking

  2020cited by this paper
• Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer

  2020cited by this paper
• Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells

  2020cited by this paper
• Current perspectives on inhibitory SMAD7 in health and disease

  2020cited by this paper
• Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β

  2020cited by this paper
• Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1

  2020cited by this paper
• Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.

  2020cited by this paper
• TGFβ inhibition via CRISPR promotes the long-term efficacy of CAR-T cells against solid tumors.

  2020cited by this paper
• Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort

  2020cited by this paper
• Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

  2020cited by this paper
• TGFβ biology in cancer progression and immunotherapy

  2020cited by this paper
• A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys.

  2020cited by this paper
• Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with non-small cell lung cancer: results from an expansion cohort of a phase 1 trial.

  2020cited by this paper
• Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity

  2020cited by this paper
• Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

  2020cited by this paper
• TGF-β suppresses type 2 immunity to cancer

  2020cited by this paper
• Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses.

  2020cited by this paper
• Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

  2020cited by this paper
• Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer

  2020cited by this paper
• Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety‐Assessment Cohort

  2020cited by this paper
• Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

  2019cited by this paper
• Trades

  2019cited by this paper
• Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

  2019cited by this paper
• Transforming Growth Factor-beta signaling in αβ thymocytes promotes negative selection

  2019cited by this paper
• A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment

  2019cited by this paper
• Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies

  2019cited by this paper
• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

  2019cited by this paper
• Tumor-derived TGF-β inhibits mitochondrial respiration to suppress IFN-γ production by human CD4+ T cells

  2019cited by this paper
• Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy

  2019cited by this paper
• TGFβ1 is essential for MSCs-CAFs differentiation and promotes HCT116 cells migration and invasion via JAK/STAT3 signaling

  2019cited by this paper
• Chimeric antigen receptors designed to overcome transforming growth factor‐β‐mediated repression in the adoptive T‐cell therapy of solid tumors

  2019cited by this paper
• TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis

  2019cited by this paper
• Transforming Growth Factor-β Signaling in Immunity and Cancer.

  2019cited by this paper
• Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

  2019cited by this paper
• α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

  2019cited by this paper
• Specificity, versatility, and control of TGF-β family signaling

  2019cited by this paper
• Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis

  2019cited by this paper
• Tumor mutational load predicts survival after immunotherapy across multiple cancer types

  2019cited by this paper
• Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

  2018cited by this paper
• Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

  2018cited by this paper
• CD4+ T cell help in cancer immunology and immunotherapy

  2018cited by this paper
• TGFBI Expressed by Bone Marrow Niche Cells and Hematopoietic Stem and Progenitor Cells Regulates Hematopoiesis

  2018cited by this paper
• Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

  2018cited by this paper
• Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.

  2018cited by this paper
• Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

  2018cited by this paper
• Stromal Fibroblasts Mediate Anti–PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma

  2018cited by this paper
• Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment

  2018cited by this paper
• TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure

  2018cited by this paper
• Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

  2018cited by this paper
• Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer

  2018cited by this paper
• Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.

  2018cited by this paper
• Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

  2018cited by this paper
• Human TGF-β1 deficiency causes severe inflammatory bowel disease and encephalopathy

  2018cited by this paper
• A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

  2018cited by this paper
• TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

  2018cited by this paper
• Immune checkpoint blockade combined with IL‐6 and TGF‐β inhibition improves the therapeutic outcome of mRNA‐based immunotherapy

  2018cited by this paper
• Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

  2018cited by this paper
• TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure

  2018influential reference
• M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

  2018cited by this paper
• TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

  2018influential reference
• IDO1 in cancer: a Gemini of immune checkpoints

  2018cited by this paper
• Resident memory T cells, critical components in tumor immunology

  2018cited by this paper
• The Mechanisms of T Cell Selection in the Thymus.

  2017cited by this paper
• Induction of resident memory T cells enhances the efficacy of cancer vaccine

  2017cited by this paper
• Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

  2017cited by this paper
• Targeting TGF-β Signaling in Cancer.

  2017cited by this paper
• Transforming Growth Factor Beta-2 Mutations in Barlow's Disease and Aortic Dilatation.

  2017cited by this paper
• TGF-β Family Signaling in the Control of Cell Proliferation and Survival.

  2017cited by this paper
• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  2017cited by this paper
• The ILK-MMP9-MRTF axis is crucial for EndMT differentiation of endothelial cells in a tumor microenvironment.

  2017cited by this paper
• Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

  2017cited by this paper
• Force interacts with macromolecular structure in activation of TGF-β

  2017cited by this paper
• Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.

  2017cited by this paper
• CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness

  2017cited by this paper
• The Cytokine TGF‐&bgr; Promotes the Development and Homeostasis of Alveolar Macrophages

  2017cited by this paper
• TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota

  2017cited by this paper
• Transcriptional Control by the SMADs.

  2016cited by this paper
• Genomic analyses identify molecular subtypes of pancreatic cancer

  2016cited by this paper
• TGF-β Signaling from Receptors to Smads.

  2016cited by this paper
• Immunoregulation by members of the TGFβ superfamily

  2016cited by this paper
• Surface Expression of TGFβ Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer.

  2016cited by this paper
• Transforming Growth Factor β Drives Hemogenic Endothelium Programming and the Transition to Hematopoietic Stem Cells

  2016cited by this paper
• TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway

  2016cited by this paper
• Signaling Receptors for TGF-β Family Members.

  2016cited by this paper
• Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins.

  2016cited by this paper
• Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.

  2016cited by this paper
• TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology.

  2016cited by this paper
• Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.

  2016cited by this paper
• A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.

  2016cited by this paper
• TGFβ Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment.

  2016cited by this paper
• Cancer Immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

  2016cited by this paper
• Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions.

  2015cited by this paper
• Dynamics of B cells in germinal centres

  2015cited by this paper
• Stromal contribution to the colorectal cancer transcriptome

  2015cited by this paper
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  2015cited by this paper
• The Consensus Molecular Subtypes of Colorectal Cancer

  2015cited by this paper
• Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

  2015cited by this paper
• Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo

  2015cited by this paper
• Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation

  2015cited by this paper

• New Hepatocellular Carcinoma (HCC) Primary Cell Cultures as Models for Exploring Personalized Anti-TGF-β Therapies Based on Tumor Characteristics

  2025cites this paper
• Co-expression of a truncated TGFβ receptor II in c-Met CAR T cells enhances antitumor activity against lung adenocarcinoma

  2025cites this paper
• TGFβ in malignant canine mammary tumors: relation with angiogenesis, immunologic markers and prognostic role

  2024cites this paper
• The role of transforming growth factor-β (TGF-β) in the formation of exhausted CD8 + T cells

  2024cites this paper
• Implications of single-cell immune landscape of tumor microenvironment for the colorectal cancer diagnostics and therapy

  2023cites this paper
• Mechanisms driving the immunoregulatory function of cancer cells

  2023cites this paper
• Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression

  2022cites this paper
• TIMP1 and TIMP2 Downregulate TGFβ Induced Decidual-like Phenotype in Natural Killer Cells

  2021cites this paper
• The Role of TGF-β in Bone Metastases

  2021cites this paper